Joseph Papa compensation by year
Bausch & Lomb Summary Compensation Table · all 4 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Salary | $1,526,539 | $1,600,000 | $1,600,000 | $283,077 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $8,127,907 | $16,561,105 | $8,499,996 | $0 |
| Option awards | $2,251,352 | $2,250,054 | $8,499,996 | $0 |
| Non-equity incentive | $2,160,000 | $2,448,000 | $1,128,000 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $53,563 | $29,978 | $53,769 | $9,245,009 |
| Total | $14,119,361 | $22,889,137 | $19,781,761 | $9,528,086 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bausch & Lomb Corp DEF 14A filed April 29, 2024, accession 0001308179-24-000628, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Bausch & Lomb Corp filed document, accession 0001308179-24-000628. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 1,248,496 | — | $18.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Bausch & Lomb Corp's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Bausch & Lomb’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Brenton Saunders | Chairman of the Board and Chief Executive Officer | $45,309,051 |
| Joseph Papa · this page | Former Chief Executive Officer | $9,528,086 |
| Christina Ackermann | Former Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals | $6,091,013 |
| Joseph Gordon | Former President, Global Consumer, Surgical and Vision Care | $5,260,130 |
| A. Robert Bailey | Executive Vice President & Chief Legal Officer | $5,214,599 |
| Sam Eldessouky | Executive Vice President and Chief Financial Officer | $4,757,166 |
| Yehia Hashad | Executive Vice President of Research & Development and Chief Medical Officer | $2,657,494 |
| Andrew Stewart | President, Global Pharmaceuticals and International Consumer | $1,933,266 |
The full Bausch & Lomb compensation record
free company briefThis page is one person within Bausch & Lomb's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Bausch & Lomb proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Bausch & Lomb's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.